Prepartum Nevirapine Improves Outcome With Third Trimester Zidovudine

A single dose of nevirapine given prepartum further reduced perinatal human immunodeficiency virus (HIV) transmission compared with third trimester dosing of zidovudine alone, according to the results of a randomized trial published in the July 15 issue of the New England Journal of Medicine. But adding nevirapine to the infants’ one-week regimen of zidovudine did not improve the outcome further. A second study showed that a single prepartum dose of nevirapine may reduce the mother's response to nevirapine-containing highly active antiretroviral therapy (HAART) regimens six months later.